Surrozen, Inc.
NASDAQ:SRZNBiotechnology
-$1.14 today
- Market cap
- $237.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
Volume 0.31M
Average 0.11M
SRZN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Surrozen, Inc.NASDAQ: SRZN
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.11M rose 152.4% year over year, ahead of the +30.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 110.1% from the prior quarter. Over 3 fiscal years it compounded at -5.3% a year.
Context
- Stock-based compensation amounted to 110.3% of revenue in FY2025, up 71.7 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +152.4% holds above the trailing-twelve-month pace of +30.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 3.84M USD
- Year-over-year change
- -6.8%
- 4-year CAGR
- +13.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.84M | -6.8% |
| FY2024 | 2024-12-31 | 4.11M | -5.9% |
| FY2023 | 2023-12-31 | 4.37M | -3.2% |
| FY2022 | 2022-12-31 | 4.52M | +95.0% |
| FY2021 | 2021-12-31 | 2.32M | — |
Stock-Based Compensation vs competitors
How SRZN compares with its peers on the latest reported figures
- SRZN's LTM Mar 2026 stock-based compensation of $5.11M is the 4th largest of the 8 companies compared; the peer median is $4.63M.
- Its year-over-year change of +30.3% is the highest of 8, against a peer median of -42.1%.
- Stock-based compensation amounts to 68.1% of revenue for SRZN, versus a peer median of 33.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.88M | -49.1% | -22.9% | 85.6% | |
| LTM Mar 2026 | $10.29M | -14.6% | -1.8% | 8.3% | |
| LTM Mar 2026 | $6.18M | -61.9% | -34.1% | — | |
| LTM Mar 2026 | $5.11M | +30.3% | -5.3% | 68.1% | |
| LTM Mar 2026 | $4.63M | -43.5% | +57.4% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $3.95M | +20.1% | +23.4% | 33.0% |
| LTM Mar 2026 | $2.15M | -27.0% | +57.6% | — | |
| LTM Mar 2026 | $1.83M | -42.1% | -16.4% | — | |
| Peer median (excluding SRZN) | $4.63M | -42.1% | -1.8% | 33.0% | |
Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (54.65M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Depreciation & Amortization | 2.07M | 1.96M | 1.91M | 1.44M | 537K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.32M | 4.52M | 4.37M | 4.11M | 3.84M |
| Change in Working Capital | (221K) | (8.42M) | (3.93M) | (836K) | 3.15M |
| Accounts Receivables | 0 | (1.98M) | 0 | (502K) | 2.33M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 857K | (2.04M) | (133K) | (228K) | 142K |
| Other Working Capital | (1.08M) | (4.4M) | (3.8M) | (106K) | 678K |
| Other Non-Cash Items | 1.67M | (6.2M) | 325K | 41.22M | 204.26M |
| Operating Cash Flow | (48.81M) | (44.15M) | (40.36M) | (17.63M) | (30.24M) |
| Capital Expenditures | (1.27M) | (728K) | (398K) | (26K) | (128K) |
| Acquisitions (Net) | 0 | (39.04M) | 0 | 0 | 0 |
| Purchases of Investments | (91.74M) | (29.6M) | (28.04M) | 0 | 0 |
| Sales of Investments | 15.3M | 68.64M | 80.17M | 0 | 0 |
| Other Investing Activities | 0 | 39.04M | 0 | 0 | 0 |
| Investing Cash Flow | (77.71M) | 38.31M | 51.72M | (26K) | (128K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 124.22M | 42K | 280K | 16.04M | 85.05M |
| Common Stock Repurchased | 0 | (2.61M) | (4K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 410K | (85K) | 280K | 133K | 0 |
| Financing Cash Flow | 124.63M | (2.57M) | 276K | 16.18M | 85.05M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.89M) | (8.4M) | 11.64M | (1.48M) | 54.68M |
| Free Cash Flow | (50.08M) | (44.87M) | (40.76M) | (17.65M) | (30.37M) |
Surrozen, Inc.
NASDAQ:SRZN
Intrinsic Alpha fair value
Locked
Current Price
$31.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.